Articles tagged with Cancer Medication
The COVID-19 pandemic had a significant impact on prescription drug spending in the US, with increased utilization and uptake of biosimilars driving growth. Specialty medications are also expected to play a major role in shaping future drug expenditures.
A new study from Ohio State University reveals that women with high-risk profiles struggle to access genetic counseling and testing due to financial constraints. The research emphasizes the need for greater transparency in healthcare pricing and policies to eliminate barriers to early cancer detection.
A global phase 3 clinical study confirms the effectiveness of targeted antibody drug conjugates against refractory metastatic triple-negative breast cancer. The ADC drug sacituzumab govitecan delivered a high dose of a cancer-killing drug to tumor cells, improving progression-free and overall survival.
A chemist at Purdue University has found a way to synthesize a compound that can fight a previously 'undruggable' cancer protein with benefits across various cancer types. The compound, curcusone D, was discovered in a shrub native to North America and has shown potent anti-cancer activity against breast cancer cells.
Researchers at VCU Massey Cancer Center have identified a protein called PLK3 that operates with mutated p53 genes to spur lung cancer growth. Inhibiting PLK3 has been shown to reduce tumor cell formation and proliferation in preclinical models of lung cancer.
The company's Abiprot technology identifies antibody binding sites on native-state, disease-relevant proteins at high resolution. The platform has the potential to bring game-changing benefits to large populations of patients suffering from uncurable diseases.
Australian researchers have discovered a new therapeutic approach for treating Diffuse Intrinsic Pontine Glioma (DIPG), a currently incurable brain cancer in children. Using the anti-cancer compound CBL0137, which targets the key genetic driver of DIPG, has shown promising results in both laboratory tests and animal models.
A new study reveals a long-sought enzyme, AMBRA1, that prevents cancer by controlling proteins driving cell growth. The findings also suggest that an existing drug class may be able to reverse such defects in the future.
Researchers at University Health Network found that combining immune-boosting drugs with radiation and surgery increased survival and anticancer immune response in mouse models of mesothelioma. The treatment extended survival and provided a durable immune response, even after re-injection of tumour cells up to 12 weeks later.
A new study suggests that immunotherapies combined with phenformin may be an effective way to fight cancer. Researchers found that phenformin has structural and therapeutic advantages over its sister compound metformin, which was previously used as an anti-diabetic agent.
Researchers at Ohio State University suggest that an oral drug currently used to treat neuromuscular diseases could help prevent a common form of skin cancer caused by UVB radiation. The study found that the neurotransmitter dopamine can stop the development and progression of certain UVB-induced precancerous squamous skin cancers.
Researchers propose a novel therapeutic strategy combining temozolomide with dianhydrogalactitol to overcome resistance mechanisms in glioblastoma. The combination shows synergistic effects in slowing tumour growth, suggesting a promising new approach for treating aggressive brain tumors.
A new algorithm can predict which genes cause cancer without DNA sequence changes. Researchers have identified 165 previously unknown cancer genes using machine learning technology, interacting closely with well-known cancer genes.
A large-scale study found that 25.1% of patients on immune checkpoint inhibitors developed skin-related side effects, including itching, inflammation, and rash. The study identified 10 specific conditions at higher risk among melanoma or kidney cancer patients.
Researchers at Dana-Farber Cancer Institute found that patients with non-small cell lung cancer and low aneuploidy levels tend to have better outcomes following treatment with immune checkpoint inhibitors. These findings suggest that aneuploidy testing can help determine which treatment is most likely to benefit patients.
A new combination drug therapy using a live common cold virus has demonstrated safety and efficacy against advanced skin cancer. The treatment shrunk melanoma tumors in nearly half of patients, with some experiencing complete remission.
Researchers at the Francis Crick Institute found that blocking a specific protein, DNPH1, sensitised BRCA-defective cancer cells to treatment with PARP inhibitors. The discovery suggests a promising potential treatment combination that could lead to improved therapy for patients with inheritable breast cancers.
Researchers have found a way to make cell cultures respond more closely to normal cells, allowing drugs to be screened for toxicity earlier in the research timeline. By changing two components of the media used to culture the cells, they can make liver cancer cells behave more like normal liver cells.
Researchers discovered a direct link between Parkin and the activation of mitophagy in Parkinson's, as well as its role in type 2 diabetes and cancer. The study found that AMPK, ULK1, and Parkin form a crucial pathway in cellular stress response.
Scientists have developed novel multi-stimuli-responsive drug delivery systems using hydrogels that can release drugs in response to temperature, pH, and reducing conditions. The hydrogels can control the amount of drug loaded onto them, ensuring effective delivery to target tumor sites.
Researchers at IRB Barcelona have discovered the HMCES enzyme to be a Achilles heel of some lung tumours with high mutations caused by the APOBEC system. Blocking HMCES is damaging to cancer cells but less so for healthy cells, making it a promising target for future treatments.
The Bertarelli Rare Cancers Fund has awarded over $9 million in grants to nine teams representing 19 lead investigators, advancing research into rare cancers that affect tens of thousands of patients annually. The fund aims to improve detection, diagnosis, treatment, and prevention of rare cancers through multidisciplinary collaborations.
Researchers have identified key mechanisms that enable cancer cells to resist therapies targeting mutated KRAS protein. The findings suggest a potential role for rational drug design and combination therapy in overcoming resistance.
Researchers at Niigata University have identified a protein biomarker, APM2, that can indicate the permissible level of the chemotherapeutic drug cisplatin. The study found a significant relationship between high APM2 expression and cisplatin resistance in liver and gastric cancer cells.
A study found that human tumor cells in patient-derived xenografts (PDX) are often compromised by mouse viruses, leading to false-positive results for cancer drug efficacy. The researchers analyzed 184 data sets and found that 170 samples showed the presence of mouse viruses.
A study by CU Cancer Center researcher Joaquin Espinosa and his team discovered that oxygen deprivation initially suppresses tumor growth, but later promotes metastasis. The researchers hope to develop therapies targeting specific processes in cancer cells at different stages of hypoxia.
A cohort study of 672 cancer patients found a cumulative incidence of venous thromboembolism at 12.9% and arterial thromboses at 1.8%. This risk appears to be independent of underlying cancer type or immune checkpoint inhibitor used.
Researchers at WashU Medicine found that administering chemotherapy drug temozolomide in the morning improved overall survival by about 4 months compared to evening, with an average increase of 3.5 months in patients with MGMT methylated tumors. The study suggests that adjusting timing of standard treatment could enhance effectiveness.
New research from the University of East Anglia reveals comorbidities such as heart disease, respiratory disease, and obesity increase mortality rates in COVID-19 patients. Blood pressure medications found to be protective against severe outcomes.
The funding supports development of a new drug testing platform to predict treatment outcomes for patients with cancer. Researchers will leverage tissue bioengineering advances and genomic technologies to reconstruct and grow patient-derived tumor organoids in the presence of different drugs.
Researchers at VCU Massey Cancer Center developed a bespoke therapy combining phenformin and AZD3965 to exploit the metabolic 'hunger' of aggressive neuroblastoma, leading to greater tumor shrinkage without collateral damage. The treatment showed promising results in mice seeded with MYCN-amplified neuroblastoma patient cells.
Researchers at Hokkaido University developed a hydrogel that rapidly reprograms differentiated cancer cells into cancer stem cells within 24 hours. The study has significant implications for developing targeted anti-cancer therapies and personalized medicines by targeting cancer stem cells, which are resistant to current treatments.
Oak Ridge National Laboratory (ORNL) has produced a key radioisotope, actinium-225 nitrate, for pharmaceutical companies developing new cancer treatments. ORNL's production of Ac-225 enables the support of applications without disclosing proprietary information, fulfilling FDA requirements.
Researchers used an FDA-approved cancer drug to blunt the effects of a toxic COVID-19 viral protein on human cells. The study found that the drug improved cell survival by 12% and restored damaged cellular functions.
A new study reveals that patients with newly diagnosed incurable cancer experience significant physical and emotional distress, including anxiety and depression. Comprehensive palliative care services are essential to address these needs and improve quality of life for patients.
Researchers from Queen Mary University of London developed a machine learning algorithm that ranks cancer drugs based on their effectiveness in reducing cancer cell growth. The approach has the potential to advance personalized therapies by allowing oncologists to select the best drugs for individual patients.
A new study found that a second drug targeting KRASG12C showed promising results in treating non-small-cell lung cancer (NSCLC) with this specific mutation. Nearly half of patients evaluable for clinical activity had a partial response to treatment, setting up potential future trials and combinations.
Studies found that disrupting interaction between p53 and Mdm2 in tumor cells is less effective than thought, as it can impair immune cell function. New compound APG115 showed promise in boosting T cell activity against cancer, suggesting a potential therapeutic approach.
A recent survey of nearly 7,500 physicians globally found that burnout has reached a very high rate, with women in healthcare suffering the most. The COVID-19 pandemic has exacerbated this issue, and policymakers must work with the scientific community to develop a comprehensive burnout prevention strategy.
Exposure to hydroxyprogesterone caproate during pregnancy has been linked to a higher risk of early-onset cancer in offspring, particularly colorectal and prostate cancers. The study found that adult children of mothers who received the drug had more than twice the odds of cancer.
Researchers at Boston University School of Medicine have found that PXS-LOX_1 and PXS-LOX_2 can slow primary myelofibrosis's disease progression in experimental models by inhibiting lysyl oxidase. These findings represent a possible novel avenue for treatment, potentially slowing cancer progression and easing symptoms.
Researchers have developed a nondestructive way to measure drug treatment responses in lab-grown cancer samples using redox imaging. The technique allows for sensitive information about drug responsiveness and can identify organoid subpopulations with distinct responses.
Researchers found that ibuprofen inhibits the alternative splicing event generating RAC1B, overexpressed in BRAF-mutated colorectal tumors. Ibuprofen disrupts a WNK1/GSK3β/SRPK1 protein kinase complex, promoting nuclear exclusion of SRPK1 and SRSF1.
Endogenous Cushing's syndrome is associated with a threefold increase in death, primarily due to cardiovascular disease and infections. The study analyzed data from over 19,000 patients and found that mortality rates were lower after 2000, but still unacceptably high.
A recent study published by The Endocrine Society has found that commonly used medications for type 2 diabetes and obesity, known as GLP-1 RAs, are not associated with an increased risk of breast cancer. This new research provides relief to concerns arising from previous clinical trials of liraglutide.
Researchers have identified a small molecule drug candidate that targets the uptake of glutamine in cancer cells, slowing the growth of melanoma and other cancers. The study, published in Molecular Cancer Therapeutics, offers an exciting new therapeutic approach for treating tumors addicted to glutamine.
The LSU Veterinary School has received a $11 million grant from the National Institutes of Health to create a Center for Pre-Clinical Cancer Research, which aims to develop more effective anti-cancer treatments. The new center will provide specialized core facilities and training opportunities for researchers.
Scientists at Karolinska Institutet have determined the 3D structure and mechanism of MGST2, an enzyme involved in oxidative stress and DNA damage. The study's findings reveal three functional units controlled by sophisticated movements, regulating vital functions and offering insights into future drug development.
Scientists at Tokyo Medical and Dental University identified a combination of pitavastatin and capmatinib as effective in inhibiting oral cancer cell growth. This breakthrough provides new hope for treating devastating diseases like esophageal carcinoma, which has no targeted therapies.
Researchers discovered that varying levels of a DNA repair enzyme called AAG can lead to different outcomes after exposure to NDMA, a probable carcinogen. High levels of AAG can cause tissue damage and cell death, while low levels can result in more cancer mutations.
A new grant will enable researcher Neil Box to conduct further follow-up work with a longitudinal study of mole development in kids, aiming to determine the effects of early sun exposure. The study aims to develop more sophisticated measures of sun damage and explore its relationship with melanoma risk.
Researchers at Duke-NUS Medical School and A*STAR discovered that inhibiting the Wnt signalling pathway with ETC-159 can reverse PARP inhibitor resistance in several cancer cell lines. This breakthrough could lead to novel anti-cancer treatments for cancers with overactive Wnt signalling, such as colorectal cancer.
Researchers will explore the impact of COVID-19 on blood sugar management in children with type 1 diabetes and obesity. Emerging studies will examine the implications for individuals with high blood sugar levels, adrenal insufficiency, and vitamin D deficiency.
A Northwestern University team developed an experimental drug that crosses the blood-brain barrier and triggers death of tumor cells. The spherical nucleic acid (SNA) drug has shown promise for treating other neurological diseases like Alzheimer's and Parkinson's.
The CCE-DART project aims to develop interconnected tools to reduce the complexity of investigator-initiated trials, incorporating cutting-edge digital technologies. It will harmonize molecular multi-tier profiling platforms to precisely match patients to novel anti-cancer medicines based on genetic tumor specificities.
Researchers at Hebrew University have developed human-on-a-chip technology that allows for real-time monitoring of drug treatments in humans. The technology has the potential to significantly reduce testing and production time for drugs, saving time, money, and unnecessary suffering.
Researchers developed a tumor-penetrating peptide that can deliver chemotherapy drugs deep into pancreatic cancer tumors, increasing effectiveness and reducing metastasis. The therapy showed promising results in animal models, with significant increases in survival and reductions in cancer spread.
A new study found that global clinical trials enrolled less than half the proportion of Black patients as U.S. trials, highlighting a trend that may exacerbate racial disparities in cancer research and care. The study suggests that globalization of cancer clinical trials may be a key driver of these disparities.
A study found that night shifts disrupt natural rhythms in cancer-related genes, making workers more vulnerable to DNA damage. This can lead to increased cancer risk, and researchers hope to develop prevention strategies and treatment options to address this issue.
Researchers have developed a new inhibitor that targets the multi-drug resistant protein 4 (MRP4), blocking its transport of cancer-promoting messengers and allowing chemotherapy to work again. This could improve treatment options for persistent cancers.